Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acecainide pharmacokinetics in normal subjects of known acetylator phenotype.

Biopharmaceutics & drug disposition - 1 Nov 1991

Coyle J D, Boudoulas H, Lima J J

Abstract excerpt

The purpose of this study was to determine the pharmacokinetics of acecainide (formerly N-acetylprocainamide) in six normal subjects of known acetylator phenotype. Three subjects were fast acetylators and three slow acetylators by sulfapyridine phenotyping criteria. Each subject received a 20-min, 3 mg kg-1 intravenous acecainide infusion. Concentrations of acecainide, procainamide, and their deethylated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetylation
Share to Phenotype

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 1724922
DOI: 10.1002/bdd.2510120806

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acecainide pharmacokinetics in normal subjects of known acetylator phenotype.PMID 1724922Read ↗

Pharmacokinetics, acetylation-deacetylation, renal clearance, and protein binding of sulphamerazine, N4-acetylsulphamerazine, and N4-trideuteroacetylsulphamerazine in 'fast' and 'slow' acetylators.Semantic proximity Read ↗

Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators.Semantic proximity Read ↗

[Pharmacokinetics of procainamide and its metabolite depending on acetylator phenotype].Semantic proximity Read ↗

Determination of the acetylator phenotype and pharmacokinetics of some sulphonamides in man.Semantic proximity Read ↗

N-acetylation phenotyping with sulphadimidine in a Turkish population.Semantic proximity Read ↗

Amantadine acetylation may be effected by acetyltransferases other than NAT1 or NAT2.Semantic proximity Read ↗

Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions.Semantic proximity Read ↗

Population pharmacokinetic analysis of isoniazid, acetylisoniazid, and isonicotinic acid in healthy volunteers.Semantic proximity Read ↗

Acetylation phenotype in hypertensive patients.Semantic proximity Read ↗

Mesalazine pharmacokinetics and NAT2 phenotype.Semantic proximity Read ↗

N-acetylation and oxidative capacity in aged volunteers determined with sulfamethazine and antipyrine.Semantic proximity Read ↗

Paradoxical relationship between acetylator phenotype and amonafide toxicity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.